Courses & Events

US-Asia Technology Management Center 2025 Annual Meeting

Wednesday, May 21, 2025

04:30 pm - 07:30 pm

During US-ATMC’s 2025 Annual Meeting US-ATMC Director Dr. Richard Dasher will discuss US-ATMC’s major accomplishments in a review of the Center’s research, education, and outreach programs over the last year, along with the Center’s plans for the 2025 – 26 academic year. We’ll also have a keynote talk from Dr. Bruce Ling, Senior Research Scientist, Pediatrics – Neonatology, and hear from US-ATMC Visiting Scholars as they present brief remarks on their activities and research findings over the past year.

Keynote speaker Dr. Bruce Ling will introduce his research group at Stanford and provide a brief overview of his collaboration with Nippon Life, an industrial affiliate member of US-ATMC. He will share his forward-looking vision for how his research aims to tackle major societal challenges and create meaningful, lasting impact.

Agenda:

• 4:30 PM US-ATMC Update and Strategic Overview from Dr. Richard Dasher, US-ATMC Director
• 4:45 PM  Keynote from Dr. Bruce Ling, Senior Research Scientist, Pediatrics – Neonatology
• 5:20 PM  Introductions to research by current US-ATMC visiting scholars

About Dr. Bruce Ling:

Dr. Ling’s investigative interests are in translation medicine that bridge mass spectrometry based high throughput biology and biomedical computation. He brings a great depth of experience and demonstrated success in using his high throughput and high content multi-omics approach to create both platforms and products with obvious translational utility.

Dr. Ling earned his PhD in Biological Chemistry in UCLA with Dr. Michael Grunstein, a member of National Academy of Sciences. After graduation, Dr. Ling did a post-doc in molecular immunology under Dr. Alan Krensky at Stanford Medicine and simultaneously trained in computer science. With the unique computational skills and knowledge of the underlying biology, Dr. Ling’s professional career launched in the early days of the human genome project completion to decode for innovative drug targets. Bruce quickly advanced over the course of five years from a Bioinformatics Scientist to Research Director at Tularik Inc, an early and highly successful biotechnology start-up founded by Dave Goeddel who is legendary in the biotechnology field. When Tularik was acquired by Amgen, Dr. Ling stayed on at Amgen as Director of Research. Dr. Ling returned to Stanford in 2006 and brought with him his industry experience in creating high throughput laboratory and computational platforms for high content biomedical discoveries. During his tenure at Stanford, Dr. Ling has been instrumental in creating the mass spectrometry based infrastructure and associated computational platform to support diagnostic biomarker discovery and more recently in providing mechanism of disease insight. Throughout his career both in industry and academia, Dr. Ling has maintained a passion for mentoring others. His CV details a long list of highly successful trainees and students. It is also apparent that Dr. Ling has established numerous fertile collaborations both within the Stanford community as well as with other leading scientists in academia and industry.